What is Retatrutide?
Retatrutide is a synthetic peptide composed of 42 amino acids. It is a triple-acting agonist, simultaneously activating the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. This unique triple activity distinguishes it from other incretin analogues and expands its metabolic effects. It was originally developed for the treatment of type 2 diabetes mellitus and obesity. In clinical studies, a pronounced effect on body weight reduction, improvement in glycemic control and reduction of risk factors for cardiovascular disease was observed.
Observations on Retatrutide
Retatrutide is being studied for its possible effects on:
Blood sugar control – in research settings, a decrease in HbA1c and improvement in insulin sensitivity have been observed.
Weight reduction – in clinical models, a more pronounced effect on body fat loss has been described compared to dual agonists.
Metabolic health – an effect on improving the lipid profile and reducing hepatic steatosis has been observed.
Cardiovascular protection – reductions in triglycerides, blood pressure, and inflammatory markers have been observed in research models.
Improved energy homeostasis – an effect associated with increased fat burning and reduced appetite has been described.
Scientific data
Retatrutide has been studied in large-scale clinical trials.
In patients with type 2 diabetes mellitus, the following has been reported:
- Reduction in HbA1c by up to 2.2%
- Weight loss 15-20%
- Improvement of lipid profile and blood pressure
In obese people without diabetes, the following have been observed:
- Average weight loss of over 24% in 72 weeks
- Significant reduction of visceral fat
- Improvement of cardio-metabolic indicators
Dosage and administration
The scientific literature describes subcutaneous administration once a week.
Standard doses: start with 2 mg and gradually titrate to 4 mg weekly depending on tolerability and therapeutic effect.
At 5 mg + 2 ml bacteriostatic water:
Concentration = 2.5 mg/ml → 0.4 ml = 1 mg
Example values for 5 mg:
0.1 ml = 0.25 mg
0.2 ml = 0.5 mg
0.3 ml = 0.75 mg
0.4 ml = 1 mg
0.5 ml = 1.25 mg
At 10 mg + 2 ml bacteriostatic water:
Concentration = 5 mg/ml → 0.2 ml = 1 mg
Example values for 10 mg:
0.1 ml = 0.5 mg
0.2 ml = 1 mg
0.3 ml = 1.5 mg
0.4 ml = 2 mg
0.5 ml = 2.5 mg
Possible side effects
The most commonly reported reactions are related to the gastrointestinal tract.
Possible side effects are highly dose-dependent and include:
- nausea, vomiting, diarrhea, constipation
- decreased appetite
- abdominal discomfort
Rarer but more serious risks include:
- pancreatitis
- gallstone disease with rapid weight loss
- hypoglycemia when combined with other antidiabetic agents
The information has been collected and systematized from various scientific sources and studies. It serves educational purposes only and should not be used for the diagnosis, treatment or prevention of diseases .